HMG CoA reductase inhibitors (statins) for dialysis patients (Q24198108)

1

0 references

Jonathan Craig

Jonathan C Craig

3

0 references

David Johnson

4

David W Johnson

0 references

Giovanni Strippoli

8

Giovanni FM Strippoli

0 references

Sankar Navaneethan

2

Sankar D Navaneethan

0 references

Jörgen Hegbrant

7

Jorgen Hegbrant

0 references

Sagar U Nigwekar

6

Cochrane Database of Systematic Reviews

Sagar U Nigwekar

0 references

publication date

11 September 2013

0 references

published in

0 references

cites work

The association between parathyroid hormone and mortality in dialysis patients is modified by wasting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Glycemic control and cardiovascular events in diabetic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Rosuvastatin in diabetic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Safety and efficacy of atorvastatin in patients with severe renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

End-stage renal disease in the United States: an update from the United States Renal Data System

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

The value of lowering cholesterol after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

The ABCs of cardioprotection in dialysis patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

HGM CoA reductase inhibitors (statins) for lowering cholesterol in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

HMG CoA reductase inhibitors (statins) for dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

HMG CoA reductase inhibitors (statins) for dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

[Clinical protocol. Pravastatin for the prevention of the destruction of the nutritional status of hemodialysis patients exhibiting chronic inflammation]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Effect of simvastatin on the lipid profile of hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Poor long-term survival after acute myocardial infarction among patients on long-term dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Study of the quality of information given to patients participating in a clinical trial regarding chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004289.PUB5

7 January 2021

10.1002/14651858.CD004289.PUB5

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2597109

2597109

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference